DeepMed Research

Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy and Safety of CSA and Avatrombopag for the Treatment of SAA in the Elderly

Not Applicable

Recruiting

Conditions: Severe Aplastic Anemia

Interventions: Drug: Avatrombopag

First Posted Date: 2022-06-27

Last Posted Date: 2022-06-27

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 80

Registration Number: NCT05433922

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China

Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia

Phase 2

Recruiting

Conditions: Essential Thrombocytopenia

Interventions: Drug: Recombinant Interferon Alpha
Drug: Pegylated interferon alfa-2b

First Posted Date: 2022-05-27

Last Posted Date: 2024-07-03

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 194

Registration Number: NCT05395507

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients

Phase 2

Conditions: Acute Myeloid Leukemia
Measurable Disease

Interventions: Drug: Venetoclax, Azacitidine
Drug: Venetoclax, daunorubicin, cytarabine

First Posted Date: 2022-05-04

Last Posted Date: 2022-05-04

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 40

Registration Number: NCT05361057

Locations: 🇨🇳
HBDH, Tianjin, Tianjin, China

Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid Leukemia

Phase 2

Not yet recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: with or without venetoclax

First Posted Date: 2022-05-02

Last Posted Date: 2022-05-02

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 300

Registration Number: NCT05356169

Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia

Not Applicable

Conditions: Acute Leukemia

Interventions: Procedure: Combined haploidentical and umbilical cord blood allogeneic stem cell transplantation
Procedure: haploidentical hematopoietic stem cell transplantation

First Posted Date: 2022-04-19

Last Posted Date: 2022-08-11

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 116

Registration Number: NCT05335226

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China

GVM±R in Patients With Relapsed or Refractory Aggressive NHL

Phase 1

Active, not recruiting

Conditions: Non Hodgkin Lymphoma

Interventions: Drug: Liposomal Mitoxantrone Hydrochloride dose level 1
Drug: Liposomal Mitoxantrone Hydrochloride dose level 2
Drug: Liposomal Mitoxantrone Hydrochloride dose level 3
Drug: Liposomal Mitoxantrone Hydrochloride dose level 4

First Posted Date: 2022-03-28

Last Posted Date: 2025-05-13

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 18

Registration Number: NCT05299164

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin, Please Select, China

Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma

Phase 2

Recruiting

Conditions: Multiple Myeloma
Lymphoma

Interventions: Drug: Etoposide
Drug: Cyclophosphamide
Drug: Mecapegfilgrastim, day 5
Drug: Mecapegfilgrastim, day 2

First Posted Date: 2022-03-24

Last Posted Date: 2025-05-13

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 120

Registration Number: NCT05294055

Locations: 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

and more 4 locations

A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia

Phase 1

Active, not recruiting

Conditions: Acute Lymphocytic Leukemia

Interventions: Biological: LCAR-AIO Cells

First Posted Date: 2022-03-23

Last Posted Date: 2024-05-14

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 20

Registration Number: NCT05292898

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
🇨🇳
Beijing Gobroad BoRen Hospital, Beijing, Beijing, China

Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL

Phase 2

Not yet recruiting

Conditions: Chronic Lymphocytic Leukemia
Newly Diagnosed
Small Lymphocytic Lymphoma

Interventions: Drug: Zanubrutinib, Fludarabine, cyclophosphamide and rituximab
Drug: Zanubrutinib, bendamustine, rituximab

First Posted Date: 2022-03-18

Last Posted Date: 2022-03-31

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 63

Registration Number: NCT05287984

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

Herombopag for Chemotherapy-induced Thrombocytopenia

Phase 2

Recruiting

Conditions: Herombopag
Chemotherapy-induced Thrombocytopenia

Interventions: Drug: Herombopag

First Posted Date: 2022-02-11

Last Posted Date: 2025-02-24

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 50

Registration Number: NCT05236582

Locations: 🇨🇳
Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, Tianjin, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy